Uterine Fibroid Treatment Devices Market By Technology Type (Surgical Technique (Myomectomy and Hysterectomy), Laparoscopic techniques (Myolysis and Laparoscopic Myomectomy) Ablation Techniques (Cryoablation, Microwave Ablation, and Ultrasound Ablation (MRI-guided Focused Ultrasound (MRgFUS) and High Intensity Focused Ultrasound (HIFU)), Other Ablation Techniques) Embolization Techniques) By Mode of Treatment, By End-User, and By Region- Trends, Analysis and Forecast till 2034

Report Code: PMI14019 | Publish Date: February 2024 | No. of Pages: 170

Global Uterine Fibroid Treatment Devices Overview

Uterine Fibroid Treatment Devices Market was valued at US$ 7.2 Billion in 2024 and is projected to grow at a CAGR of 2.90% to reach US$ 9.3Billion by 2034.

Uterine fibroids also are known as leiomyomas or myomas. It is a benign growth that develops from muscle tissue of the uterus. Uterine fibroid varies from person to person in shape, size, and location, such as it may situate inside or outside the surface or within its wall. It can occur in women aged between 30-40 years.

The increasing prevalence rate of uterine fibroids among women and the rising number of patients seeking proper treatment has significantly contributed to target market growth. Growing awareness among the population and rise in the spending on healthcare infrastructure is expected to fruitful the demand for Uterine Fibroid Treatment Devices Market growth in coming years.

Uterine Fibroid Treatment Devices Market Research Report

                                For More Report Details, Download Free Sample PDF

Global Uterine Fibroid Treatment Devices Drivers & Restraints

Technological advancement and new product launches along with the rise in the regulatory approvals of a robust product portfolio of the uterine fibroid are expected to upsurge the global market growth within the forecast period.  For instance, on 13th October 2015, SonaCare Medical introduced and receives U.S. Food and Drug Administration (FDA) approval for its Sonablate High Intensity Focused Ultrasound Prostate Ablation Device. This device mainly receives authorization for prostate tissue ablation.  

Growing number of Uterine Fibroid Surgeries to propel market growth

Growth in number of Uterine Fibroid surgeries has become the major factor in target market growth. For instance, according to National Uterine Fibroids Foundation, around 600,000 hysterectomies were performed every year in the U.S. Among of these surgeries, approximately 17,000 to 300,000 hysterectomies performed for the treatment of uterine fibroids, which is projected to gain more share value over the forecast period. However, uterine fibroid treatment devices are required for surgical procedure of uterine fibroid which in turn, is anticipated to increase the demand for Uterine Fibroid Treatment Devices market growth in coming years.

Restrains:

The high risk of benign neoplasm after hysterectomy procedure and healthy tissue injury may hinder the market growth. However, high cost of surgeries has hampered the Uterine Fibroid Treatment Devices market growth.

Global Uterine Fibroid Treatment Devices Segmentations & Regional Insights

Uterine Fibroid Treatment Devices Market Segmentation

Uterine Fibroid Treatment Devices Market is segmented based on Technology Type, Mode of Treatment, End-Users and Region.

Technology Type Insight

On the basis of Technology Type, Uterine Fibroid Treatment Devices Market is segmented into Surgical Technique, Laparoscopic Techniques, Ablation Techniques and Embolization techniques. Surgical technique is further segmented into Myomectomy and Hysterectomy. Laparoscopic techniques are further divided into Myolysis and Laparoscopic Myomectomy. Ablation techniques are further classified into Cryoablation, Microwave Ablation, and Ultrasound Ablation. The Ultrasound Ablation is further categorized into MRI-guided Focused Ultrasound (MRgFUS) and High Intensity Focused Ultrasound (HIFU).

The Surgical Technique is expected to dominate the target market growth due to rising number of myomectomy and hysterectomy surgical procedures which propel market segment growth.

For instance, (March 2022), according to CDC (Centers for Disease Control and Prevention), Higher prevalence of hysterectomy which increased with age and occurred in rural women than in urban women where, 16.6% of urban women and around 28.6% of rural women were reported with higher rate of hysterectomy surgical procedures.

Mode of Treatment Insights

On the basis of Mode of Treatment, Uterine Fibroid Treatment Devices Market is segmented into Minimally Invasive Treatment, Invasive Treatment and Non-Invasive Treatment. Minimally Invasive Treatment is expected to dominate the target market growth due to growing incidence of uterine fibroid diseases, technological advancement and requires smaller incision with less scarring.

End-Users Insights

On the basis of End-Users, Uterine Fibroid Treatment Devices Market is segmented into Clinics, Hospitals and Ambulatory Surgical Center. Hospitals are expected to dominate the target market growth because of robust healthcare infrastructures, the presence of healthcare professionals, and all care facilities provided under one roof.

Regional Insights:

On region the Uterine Fibroid Treatment Devices Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American market is estimated to witness a significantly high revenue share over the forecast period, owing to the growing prevalence of uterine fibroid diseases, huge research and development activities, technological advancement, government initiatives, and robust healthcare infrastructure are anticipated to increase demand for Uterine Fibroid Treatment Devices market in the region.

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Technology Type - Surgical Technique, Laparoscopic Techniques, Ablation Techniques and Embolization Techniques

By Mode of Treatment - Minimally Invasive Treatment, Invasive Treatment and Non-Invasive Treatment

By End-Users - Clinics, Hospitals and Ambulatory Surgical Center

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Uterine Fibroid Treatment Devices Market report based on Technology Type, Mode of Treatment, End-Users and Region.

Uterine Fibroid Treatment Devices Market, By Technology Type:

  • Surgical Technique
  • Myomectomy
  • Hysterectomy
  • Laparoscopic Techniques
  • Myolysis
  • Laparoscopic Myomectomy
  • Ablation Techniques
  • Cryoablation
  • microwave Ablation
  • Ultrasound Ablation
  • MRI-guided Focused Ultrasound (MRgFUS) 
  • High Intensity Focused Ultrasound (HIFU)
  • Other Ablation Techniques
  • Embolization Techniques

Uterine Fibroid Treatment Devices Market, By Mode of Treatment:

  • Minimally Invasive Treatment
  • Invasive Treatment
  • Non-Invasive Treatment

Uterine Fibroid Treatment Devices Market, By End-Users:

  • Clinics
  • Hospitals
  • Ambulatory Surgical Center

Uterine Fibroid Treatment Devices Market, By Region:

 

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

Global Uterine Fibroid Treatment Devices Competitive Landscape & Key Players

The key players operating the Uterine Fibroid Treatment Devices Market includes, Boston Scientific Corporation, CONMED Corporation, PENTAX Medical, Advanced Surgical Concepts, PLLC, Ethicon, Inc., Hologic, Inc., Medtronic, Plc, CooperSurgical, Inc., Olympus Corporation, and Stryker Corporation.

Global Uterine Fibroid Treatment Devices Recent News

Recent Development:

  • In July 2020, Gynesonics launched new “Sonata System” with transcervical fibroid ablation system that integrates ultrasound and uses RF (radiofrequency) energy for treating symptomatic uterine fibroids. New launched system is delivered by one integrated hand-piece through cervix and vagina into uterus for ablating uterine fibroids by causing them to shrink and to relieve symptoms for patients.
  • In November 2022, Medtronic Private limited launched new “ TruClear” system a mechanical hysteroscopic system for removal of tissues and thus used for safe and effective treatment of IUA (intra uterine abnormalities) which includes, polyps, fibroids, hyperplasia, adhesions, malignancies and conception.
  • In November 2022, Olympus launched new gynecologic device “Power Morcellator” for low risk hysterectomy and myomectomy patients. New launched tissue extraction system is first containment device that provides laparoscopic surgical option as an alternative for open myomectomy and open hysterectomy tissue removal.
  • In July 2021, Medtronic plc., launched new first robotic-assisted gynecological procedures with “Hugo” a RAS (robotic assisted surgery system). New launched “Hugo” system offers benefits of minimally invasive surgery and joins portfolio of gynecological products to enable less invasive surgical treatment for uterine fibroids, uterine bleeding and endometrial cancer.

Global Uterine Fibroid Treatment Devices Company Profile

  • Boston Scientific Corporation*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • CONMED Corporation
  • PENTAX Medical
  • Advanced Surgical Concepts PLLC
  • Ethicon, Inc.
  • Hologic, Inc.
  • Medtronic, Plc.
  • CooperSurgical Inc.
  • Olympus Corporation
  • Stryker Corporation

“*” marked represents similar segmentation in other categories in the respective section

FAQs

The Uterine Fibroid Treatment Devices Market is segmented into Technology Type, Mode of Treatment, End-Users and Region.

Uterine Fibroid Treatment Devices Market is driven by factors like technological advancement and new product launches and growth in number of Uterine Fibroid surgeries.

By region, the Uterine Fibroid Treatment Devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.

The key players operating the Uterine Fibroid Treatment Devices Market includes, Boston Scientific Corporation, CONMED Corporation, PENTAX Medical, Advanced Surgical Concepts, PLLC, Ethicon, Inc., Hologic, Inc., Medtronic, Plc, CooperSurgical, Inc., Olympus Corporation, and Stryker Corporation.

Uterine Fibroid Treatment Devices Market accounted for US$ 6.0 billion in 2022 and is estimated to be US$ 15.6 billion by 2032 and is anticipated to register a CAGR of 9.4%.